close
Add to watchlist
Genzyme Corp (GENZ) Healthcare, Biotechnology & Drugs
Genzyme Corporation operates as a biotechnology company worldwide. The company's Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and Type 3 Gaucher diseases; Fabrazyme, a recombinant form of the human enzyme alpha- galactosidase for the treatment of Fabry disease; Myozyme as a therapy for Pompe disease; and Aldurazyme for the treatment of Mucopolysaccharidosis I. This segment markets and sells its products directly to physicians, hospitals, treatment centers, pharmacies, and government agencies through distributors. Its Cardiometabolic and Renal segment develops, manufactures, and distributes products consisting of Renagel and Renvela for the control of serum phosphorus in patients with chronic kidney disease on dialysis; Hectorol, a line of vitamin D2 pro-hormone products for the treatment of secondary hyperparathyroidism; and Thyrogen, an adjunctive diagnostic agent used in the follow-up of patients with well-differentiated thyroid cancer. This segment sells its products to retail pharmacies, hospitals, and other providers of medication to patients. The company's Biosurgery segment provides biotherapeutics and biomaterial-based products, which comprise Synvisc, a biomaterial-based product that is used to treat the pain associated with osteoarthritis of the knee; and Sepra family of products to prevent adhesions following various surgical procedures in the abdomen and pelvis. Its Hematologic Oncology segment develops products for the treatment of cancer, which include Campath for the treatment of B-cell chronic lymphocytic leukemia; Clolar for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia; and Mozobil for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. The company was founded in 1981 and is based in Cambridge, Massachusetts.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.00 |
| Volume | 0 |
| Volume Avg | 0 |
| 52 Week High | 0.00 |
| 52 Week Low | 0.00 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | 0.00 |
| EPS change Q/Q | 574.07% |
| EPS change Q/Q Yr ago | 1922.22% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | -5.45% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | -99.89% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |